title: [Hange-Shashin-to for preventing diarrhea during afatinib therapy].
abstract: Afatinib is an epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI). In a randomized phase III study(Lux- Lung 3 study)employing patients harboring EGFR mutations, patients administered afatinib show a significantly longer progression free survival time(PFS)than those administeredcombination chemotherapy comprising cisplatin andpemetrexed . However, most of the patients(95.2%)treatedwith afatinib experiencedd iarrhea. In the present report, 16 patients with EGFR mutations were treatedby afatinib at our institution from May 2014 to December 2014. Twelve patients were administered a diarrhea prevention herbal medicine, Hange-shashin-to. Seven of 12 patients(58%)had no diarrhea during the 28 days of therapy. All 4 of the patients who did not receive Hange-shashin-to experienced diarrhea above Grade 1 within 6 days of starting therapy. The rate of diarrhea differed significantly between the patients receiving and not receiving Hangeshashin- to. In conclusion, preventive administration of Hange-shashin-to may reduce the occurrence of diarrhea during afatinib treatment.
authors.affiliation: Dept. of Respiratory Medicine, Saitama Medical University International Medical Center.
authors.forename: Ou
authors.initials: O
authors.lastname: Yamaguchi
authors.forename: Akiko
authors.initials: A
authors.lastname: Kawashima
authors.forename: Ayako
authors.initials: A
authors.lastname: Shiono
authors.forename: Yuri
authors.initials: Y
authors.lastname: Maeno
authors.forename: Rinako
authors.initials: R
authors.lastname: Ishikawa
authors.forename: Ai
authors.initials: A
authors.lastname: Masumoto
authors.forename: Harue
authors.initials: H
authors.lastname: Utsugi
authors.forename: Hisayoshi
authors.initials: H
authors.lastname: Daito
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Okano
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Murayama
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D000077716:Afatinib; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D003967:Diarrhea / Q000517:prevention & control*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal; D011799:Quinazolines; C088236:hange-shashinto; D000077716:Afatinib; C512478:EGFR protein, human; D066246:ErbB Receptors